Association between urinary markers of Nucleic Acid Oxidation andMortality in Type 2 Diabetes A population-based cohort study

Diabetes Care

Volumn 36, Issue 3, 2013, Pages 669-676

  Broedbaek, Kasper ^a,b   Siersma, Volkert ^c   Henriksen, Trine ^a,b   Weimann, Allan ^a,b   Petersen, Morten ^a,b   Andersen, Jon T ^a,b   Jimenez Solem, Espen ^a,b   Hansen, Lars J ^c   Henriksen, Jan Erik ^d   Bonnema, Steen J ^d   De Fine Olivarius, Niels ^c   Poulsen, Henrik E ^a,b,e  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEIC ACID OXIDATION; OXIDATION; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; URINALYSIS; URINARY EXCRETION;

AGED; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACIDS; OXIDATION-REDUCTION;

EID: 84874422898     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0998     Document Type: Article

References (39)

1. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin ChemLabMed 2003;41:1144-1149
2. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010;26:150-171
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625
4. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: fromanimalmodels to clinical trials. Nat Rev Drug Discov 2009; 8:417-429
5. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589-1596
6. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetesmellitus: insights from mechanistic studies. Lancet 2008;371:1800-1809
7. Beisswenger PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 2012;42:1171-1183
8. Broedbaek K, Weimann A, Stovgaard ES, Poulsen HE. Urinary 8-oxo-7,8-dihydro-29-deoxyguanosine as a biomarker in type 2 diabetes. Free Radic Biol Med 2011;51: 1473-1479
9. Broedbaek K, Siersma V, Henriksen T, et al. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care 2011;34:2594-2596
10. Olivarius NF, Beck-Nielsen H, Andreasen AH, Hørder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetesmellitus. BMJ 2001;323: 970-975
11. Henriksen T, Hillestrøm PR, Poulsen HE, Weimann A. Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-29-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandemmass spectrometry. Free Radic Biol Med 2009;47:629-635
12. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(Suppl.):22-25
13. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(Suppl.):26-29
14. underOstgren CJ, Lindblad U, Melander A, Råstam L. Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project. Diabetes Care 2002;25:1297-1302
15. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predictmortality in NIDDM. Diabetes 1995;44:1303-1309
16. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-489
17. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418
18. Florkowski CM, Scott RS, Coope PA, Moir CL. Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. Diabetes Res Clin Pract 2001;53:113-120
19. de Fine Olivarius N, Siersma V, Nielsen AB, Hansen LJ, Rosenvinge L, Mogensen CE. Predictors of mortality of patients newly diagnosed with clinical type 2 diabetes: a 5-year follow up study. BMC Endocr Disord 2010;10:14
20. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 2010;12:537-577
21. Poulsen HE, Specht E, Broedbaek K, et al. RNA modifications by oxidation: a novel disease mechanism? Free Radic Biol Med 2012;52:1353-1361
22. Shan X, Tashiro H, Lin CL. The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 2003;23:4913-4921
23. Shan X, Lin CL. Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 2006;27:657-662
24. Shan X, Chang Y, Lin CL. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J 2007;21:2753-2764
25. Nunomura A, Tamaoki T, Tanaka K, et al. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 2010; 37:731-737
26. Isobe C, Abe T, Terayama Y. Homocysteine may contribute to pathogenesis of RNA damage in brains with Alzheimer's disease. Neurodegener Dis 2009;6:252-257
27. Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999;19:1959-1964
28. Abe T, TohgiH, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002;70:447-450
29. Nunomura A, Perry G, Hirai K, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 1999;893:362-364
30. Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloidbeta deposition in Down syndrome. J Neuropathol Exp Neurol 2000;59:1011-1017
31. KongQ, Lin CL.Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci 2010;67:1817-1829
32. Martinet W, De Meyer GR, Herman AG, Kockx MM. RNA damage in human atherosclerosis: pathophysiological significance and implications for gene expression studies. RNA Biol 2005;2:4-7
33. Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J 2011;25: 2515-2527
34. Mallat Z, Tedgui A. Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 2000;130:947-962
35. Simpson JA, MacInnis RJ, Peeters A, Hopper JL, Giles GG, English DR. A comparison of adiposity measures as predictors of all-cause mortality: the Melbourne Collaborative Cohort Study. Obesity (Silver Spring) 2007;15:994-1003
36. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
37. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57: 1349-1354
38. American Diabetes Association. Standards of medical care in diabetesd2010. Diabetes Care 2010;33(Suppl. 1):S11-S61
39. Pergola PE, Raskin P, Toto RD, et al BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365: 327-336